BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

  September 23, 2024

   · 

  7 min read
• Press Releases

  Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

  September 23, 2024

   · 

  6 min read
• Press Releases

  Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference

  September 23, 2024

   · 

  1 min read
• Press Releases

  ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

  September 23, 2024

   · 

  12 min read
• Press Releases

  Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)

  September 23, 2024

   · 

  2 min read
• Press Releases

  Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

  September 23, 2024

   · 

  6 min read
• Drug Development

  Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren’s Syndrome, a Rare Disease With Limited Treatment Options

  September 23, 2024

   · 

  9 min read
• Press Releases

  Avenacy to Share Company’s Year One Progress at CPHI Milan 2024

  September 23, 2024

   · 

  3 min read
• Press Releases

  Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

  September 23, 2024

   · 

  9 min read
• Press Releases

  Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

  September 23, 2024

   · 

  7 min read